

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

INSIDE INFORMATION COMPLETION OF THE ISSUANCE OF THE FIRST TRANCHE OF THE MEDIUM TERM NOTES 2021 IN THE PRC

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of China Resources Pharmaceutical Group Limited (the “**Company**”) is pleased to announce that China Resources Pharmaceutical Holdings Company Limited (華潤醫藥控股有限公司) (“**CR Pharmaceutical Holdings**”), a wholly-owned subsidiary of the Company, has completed the issuance of the first tranche of medium term notes for the year of 2021 (the “**Medium Term Notes 2021**”) in the PRC on 23 June 2021. The first tranche of the Medium Term Notes 2021 have been issued in a principal amount of RMB2.5 billion with a term of three years and a coupon rate of 3.50% per annum. Such Medium Term Notes 2021 are issued pursuant to the notice of acceptance of registration (Zhong Shi Xie Zhu [2021] No. DFI6) (the “**Notice**”) dated 26 February 2021 issued by the National Association of Financial Market Institutional Investors in relation to the proposed issuance of debt financing instruments by CR Pharmaceutical Holdings in the People’s Republic of China. The Notice shall be effective for a period of two years from the issue date of the Notice, during which CR Pharmaceutical Holdings may issue debt financing instruments including ultra short-term debentures, short-term debentures, medium-term notes, perpetual notes, asset-backed medium-term notes and green bonds in tranches.

The proceeds raised from the issuance of the first tranche of the Medium Term Notes 2021 will mainly be used for the replenishment of working capital of China Resources Pharmaceutical Commercial Group Company Limited (華潤醫藥商業集團有限公司), an indirect wholly-owned subsidiary of CR Pharmaceutical Holdings.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

For and on behalf of
China Resources Pharmaceutical Group Limited
Wang Chuncheng
Chairman

Shenzhen, 23 June 2021

As at the date of this announcement, the Board comprises Mr. Wang Chuncheng as chairman and non-executive Director, Mr. Han Yuewei, Mr. Li Xiangming and Mdm. Weng Jingwen as executive Directors, Mr. Yu Zhongliang, Mdm. Guo Wei, Mr. Hou Bo and Mr. Qing Mei Ping Cuo as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.